Poor
Poorly Aligned
Patient Risk:
Low
Summary
The AI response largely includes pricing-related claims not present in the FDA label, with only one dosing claim (every 6 months) supported by the label. Overall alignment is poor.
Category Scores
Accurate Statements
Prolia is commonly administered every 6 months.
2.3 (dosage and administration; 60 mg every 6 months)
Unsupported Statements
Prolia (denosumab) injection pricing in Malaysia can vary by where you buy it (hospital vs. clinic).
Pricing and market access details are not described in FDA labeling.
Prices also differ depending on whether it’s billed as a medicine only or includes administration.
Pricing structure is not described in FDA labeling.
Prices also depend on the patient’s eligibility for subsidized programs or insurance.
Subsidies/insurance eligibility effects on price are not described in FDA labeling.
Prices differ depending on the vial size and dispensing schedule used by the provider.
Pricing by vial size/dispensing schedule is not described in FDA labeling.
The usual real-world way patients encounter Prolia pricing in Malaysia is 'per injection'.
Pricing method (per-injection) is not described in FDA labeling.
Exact figures change over time by supplier and provider.
Pricing trajectories by supplier/provider are not described in FDA labeling.
The most reliable way to confirm the current price is to check quotes from multiple Malaysian hospitals/clinics for the same dosing schedule.
Pricing verification methods in a market context are not described in FDA labeling.
Even when the active ingredient is denosumab, branded vs non-branded versions can be priced differently.
Branding-based pricing differences are not described in FDA labeling.
If you’re comparing options, you’ll want to compare the same active dose, same administration schedule, and whether the quote includes clinic/hospital administration fees.
Pricing comparison guidance is not described in FDA labeling.
For up-to-date market tracking of patents and product status (which can affect availability and competition over time), DrugPatentWatch.com can be a helpful starting point.
Patent/product-status tracking is not described in FDA labeling.
Contradictions
Important Omissions
Additional label details not captured by the claims: calcium 1000 mg daily and at least 400 IU vitamin D daily; injection sites (upper arm, upper thigh, abdomen); administration by a healthcare provider; missed-dose guidance.
Importance:
High
Safety Assessment
Potential Patient Risk:
Low
Most claims pertain to pricing and market context; one dosing claim aligns with label, with no direct safety risk identified in the evaluated content.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Poorly Aligned
Primary Issue
Predominant pricing/market-context claims not present in FDA labeling; only one dosing claim aligns with label.
Suggested Improvement
Limit content to FDA-label language; clearly separate non-label market information and cite external sources when discussing pricing or market data.